General
Preferred name
CARVEDILOL
Synonyms
CARVEDILOL PHOSPHATE ()
Carvedilol (phosphate hemihydrate) ()
BM 14190 (phosphate hemihydrate) ()
Carvedilol phosphate hemihydrate ()
BM 14190 ()
SKF 105517 ()
BM 14190 (phosphate hemihydrate)Carvedilol phosphate hemihydrate ()
Coreg / Dilatrend ()
BM-14190, SKF 105517 ()
Carvedilol phosphate hydrate ()
SK&F-105517-D ()
SKF 105517D ()
SKF-105517D ()
Coreg CR ()
Korvasan ()
BM-14.190 ()
Coreg ()
BM-14190 ()
Coronis ()
Eucardic 6.25 ()
NSC-758694 ()
Eucardic 25 ()
DQ-2466 ()
Dimitone ()
Dilatrend ()
Eucardic 12.5 ()
Eucardic 3.125 ()
BM 14.190 ()
SKF-105517 ()
BM-14-190 ()
Eucardic ()
Talliton ()
Kredex ()
C07AG02 ()
Carvedilol-d5 ()
P&D ID
PD001210
CAS
72956-09-3
107741-96-8
929106-58-1
610309-89-2
Tags
drug
natural product
biased GPCR ligand
available
Approved by
FDA
First approval
1995
2006
Drug Status
investigational
approved
Drug indication
Congestive heart failure
Anti-Anginal
Coronavirus Disease 2019 (COVID-19)
Antihypertensive
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE Carvedilol is extensively metabolized. Less than 2% of the dose was excreted unchanged in the urine.; Carvedilol is metabolized primarily by aromatic ring oxidation and glucuronidation. The oxidative metabolites are further metabolized by conjugation via glucuronidation and sulfation. The metabolites of carvedilol are excreted primarily via the bile into the feces.
DESCRIPTION Carvedilol is a non-selective β blocker (GtoPdb)
DESCRIPTION Potent CXCR2 antagonist (Tocris Bioactive Compound Library)
DESCRIPTION beta-adrenoceptor and alpha1-adrenoceptor antagonist (Tocriscreen Plus)
DESCRIPTION Antihypertensive; cardioprotective (LOPAC library)
DESCRIPTION β-adrenoceptor and α1-adrenoceptor antagonist (Tocriscreen Total)
Cell lines
4
Organisms
2
Compound Sets
38
AdooQ Bioactive Compound Library
A11843
Axon Medchem Screening Library
3456
BiasDB
Carvedilol
Cayman Chemical Bioactives
15418
26286
25218
ChEMBL Approved Drugs
CHEMBL1201167
CHEMBL723
ChEMBL Drugs
CHEMBL1201167
CHEMBL723
Concise Guide to Pharmacology 2017/18
551
Concise Guide to Pharmacology 2019/20
551
Concise Guide to Pharmacology 2021/22
551
Concise Guide to Pharmacology 2023/24
551
DrugBank
DB01136
DrugBank Approved Drugs
DB01136
DrugCentral
522
DrugCentral Approved Drugs
522
DrugMAP
DMHTEAO
DMXTCE7
DrugMAP Approved Drugs
DMHTEAO
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
551
Ki Database
Carvedilol
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL723
Mcule NIBR MoA Box Subset
MCULE-7944987271
MedChem Express Bioactive Compound Library
HY-B0006
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
0K47UL67F2
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
carvedilol
TargetMol Bioactive Compound Library
T0447
T0342
The Spectrum Collection
Tocris Bioactive Compound Library
2685
Tocriscreen Plus
2685
Tocriscreen Total
External IDs
74
Properties
(calculated by RDKit )
Molecular Weight
406.19
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
10
Ring Count
4
Aromatic Ring Count
4
cLogP
3.74
TPSA
75.74
Fraction CSP3
0.25
Chiral centers
1.0
Largest ring
6.0
QED
0.35
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Related compounds
Custom attributes
(extracted from source data)
Target Type
7-TM Receptors
Selectivity
alpha1/beta
Target
Adrenergic Receptor
Gap Junction Protein
E-selectin
NADPH dehydrogenase
Natriuretic peptides B
VCAM1
Potassium Channel
VEGFR
LDL oxidation
HIF
NADPH
Vcam
ß/a1 antagonist
Bacterial
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Angiogenesis
Cytoskeletal Signaling
Membrane Transporter/Ion Channel
Metabolism
Tyrosine Kinase/Adaptors
Chromatin/Epigenetic
Autophagy
Anti-infection
Primary Target
Non-selective Adrenergic ? Receptors
MOA
Antagonist
Adrenergic Receptor antagonist
Gap Junction Protein inhibitor
Integrin inhibitor
NADPH inhibitor
Others inhibitor
Potassium Channel inhibitor
VEGFR inhibitor
beta1-Adrenoceptor Antagonists
Member status
member
Biosynthetic Origin
Alkaloid
Therapeutic Indication
Antihypertensive
Therapeutic Class
Cardiovascular
Vasodilator Agents
Antiviral Agents
Source data